Phase 3 Study Comparing Single Injection of Ixo-vec to Aflibercept for Treating Wet Age-Related Macular Degeneration in Adults 50 and Older

What this Trial Is About

Researchers are evaluating a gene therapy called Ixoberogene Soroparvovec Ixo-vec for people with neovascular wet age-related macular degeneration nAMD, a condition that causes abnormal blood vessel growth in the retina and can lead to vision loss, especially in adults over 65. This Phase 3, randomized, double-masked study compares the effects of a single injection of Ixo-vec to the standard treatment aflibercept. The study aims to assess whether Ixo-vec is not less effective than aflibercept in improving vision, measured by changes in best corrected visual acuity BCVA at one year. Participants are assigned to one of two groups one receives three monthly aflibercept injections followed by a single Ixo-vec injection and sham injections every eight weeks the other group receives three monthly aflibercept injections, a sham injection at week one, and aflibercept every eight weeks. Treatments are delivered through intravitreal injections directly into the eye. Safety, tolerability, and vision outcomes will be closely monitored throughout the study period. During the study, participants will undergo regular eye exams to measure visual acuity and retinal health using various imaging techniques and questionnaires assessing vision-related quality of life. Researchers will track the number of aflibercept injections needed, changes in retinal thickness, and the presence of fluid in the retina. The study lasts at least 56 weeks, with key vision measurements taken at weeks 52 and 56. Safety assessments for ocular and non-ocular adverse events will also be conducted. Participants must be at least 50 years old and have active nAMD in the study eye to join.

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)